Cargando…

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer

Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujimoto, Daichi, Miura, Satoru, Tomii, Keisuke, Sumikawa, Hiromitsu, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Kijima, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Morinaga, Ryotaro, Jodai, Takayuki, Ito, Kentaro, Shiraishi, Yoshimasa, Kogure, Yoshihito, Shibaki, Ryota, Yamamoto, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988982/ https://www.ncbi.nlm.nih.gov/pubmed/36878936 http://dx.doi.org/10.1038/s41598-023-30676-y

Ejemplares similares

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
por: Kaneda, Toshihiko, et al.
Publicado: (2018)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
por: Hosoya, Kazutaka, et al.
Publicado: (2021)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
por: Fujimoto, Daichi, et al.
Publicado: (2016)

A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune
por: Kobayashi, Haruki, et al.
Publicado: (2016)

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
por: Sakata, Shinya, et al.
Publicado: (2021)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
por: Matsumoto, Kinnosuke, et al.
Publicado: (2021)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Mixed neuroendocrine–non-neuroendocrine neoplasm of the ampulla of Vater: a case report
por: Date, Kenjiro, et al.
Publicado: (2023)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
por: Wakuda, Kazushige, et al.
Publicado: (2023)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis
por: HIRASHIMA, TOMONORI, et al.
Publicado: (2014)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future
por: Wakuda, Kazushige
Publicado: (2020)

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature
por: Mori, Ryobu, et al.
Publicado: (2017)

Fibrotic Hypersensitivity Pneumonitis Diagnosed by a Re-evaluation with Bronchoalveolar Lavage at Disease Deterioration
por: Moda, Mitsuhiro, et al.
Publicado: (2022)

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
por: Suzuki, Hidekazu, et al.
Publicado: (2013)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
por: Torresan, Sara, et al.
Publicado: (2023)

Prevalence of non-pneumonic infections with SARS-correlated virus
por: Theron, Michel
Publicado: (2004)

Prevalence of non-pneumonic infections with SARS-correlated virus
por: Woo, Patrick CY, et al.
Publicado: (2004)

Prevalence of non-pneumonic infections with SARS-correlated virus
por: Yip, CW, et al.
Publicado: (2004)

Prevalence of non-pneumonic infections with SARS-correlated virus
por: Young, Megan
Publicado: (2004)

Factors associated with non-initiation of osteoporosis pharmacotherapy after hip fracture: analysis of claims data in Japan
por: Fujii, Tomoko, et al.
Publicado: (2023)

Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
por: Shibuya, Meito, et al.
Publicado: (2021)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bi3t9a8eapji0p26c3nfgl5rih